Chinese CRO WuXi PharmaTech ($WX) is on board to help Genomics England pore over samples in its massive project to sequence the genomes of 100,000 Britons. Through its NextCODE subsidiary, WuXi will help the group interpret genetic data related to cancer. NextCODE, which WuXi acquired for $65 million earlier this year, uses a huge genomic database to help physicians and investigators identify and analyze gene mutations and provide fast diagnoses. More from FierceBiotechIT